Characteristics, outcomes, and risk factors of ICANS after axicabtagene ciloleucel: Does age matter?

Kitsada Wudhikarn,Radhika Bansal,Arushi Khurana,Matthew A. Hathcock,Michael W. Ruff,Ivan D. Carabenciov,Sherri A. Braksick,N. Nora Bennani,Jonas Paludo,Jose C. Villasboas,Yucai Wang,Patrick B. Johnston,Stephen M. Ansell,Yi Lin

Characteristics, outcomes, and risk factors of ICANS after axicabtagene ciloleucel: Does age matter?

2021

Kitsada Wudhikarn
Radhika Bansal
Arushi Khurana
Matthew A. Hathcock
Michael W. Ruff
Ivan D. Carabenciov
Sherri A. Braksick
N. Nora Bennani
Jonas Paludo
Jose C. Villasboas
Yucai Wang
Patrick B. Johnston
Stephen M. Ansell
Yi Lin

e19556Background: CD19 chimeric antigen receptor T cell therapy possesses unique side effects including cytokine release syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (I...

Keywords:

CD19
Neurotoxicity Syndrome
Immune effector cell
Medicine
Immunology
Chimeric Antigen Receptor T-Cell Therapy
Cytokine release syndrome

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations